← FDA DRUG APPROVALS

FDA ANDA · ANDA219955

EVEROLIMUS

Sponsor: NOVUGEN

APPLICATION
ANDA219955
TYPE
ANDA
ORIGINAL APPROVAL
2025-10-30
LATEST ACTION
2025-10-30
ROUTE
ORAL
DOSAGE FORM
TABLET
MARKETING STATUS
Prescription

Products

EVEROLIMUSPrescription
EVEROLIMUS 7.5MG · TABLET · ORAL
EVEROLIMUSPrescription
EVEROLIMUS 2.5MG · TABLET · ORAL
EVEROLIMUSPrescription
EVEROLIMUS 10MG · TABLET · ORAL
EVEROLIMUSPrescription
EVEROLIMUS 5MG · TABLET · ORAL

Approval history

2025-10-30UNKNOWN · Original · standardAP
VIEW ON DRUGS@FDA ↗

Related on SPEQ

Pharma industry →GMP discipline →FDA drug shortages →FDA enforcement & recalls →

Source: FDA Drugs@FDA. SPEQ is not affiliated with the FDA; this is a reference view of public FDA data, not medical, legal, or regulatory advice.

Weekly Briefing

Get the Weekly GxP Briefing

Curated regulatory intelligence — enforcement, recalls, guidance, and quality signals — in one practitioner-grade email each week. Free.

Read a past issue →